Its statement also suggested the patient’s liver enzymes were elevated. That often is indicative of damage to cells in the organ, according to the Cleveland Clinic. Pfizer told CNBC that the trial ...

Tiffany & Co. unveils Bird on a Pearl in Koh Samui, where Schlumberger’s love of nature shines in rare jewels with natural saltwater pearls.

Prepare to become a mixing-and-matching maven...while freeing up some souvenir space for your visit to Florence's leather ...

Two yearbooks, from 1951 and 1926, were among the contents of a time capsule taken from the 1951 cornerstone of the Rantoul Township High School building. Counter clockwise from left, Rantoul ...

Today's super-resolution microscopes have made it possible to observe the nanoscale world with unprecedented detail. However, they require fluorescent tags, which reveal structural details but provide ...

Dr. Ho Seong Jang and colleagues at the Extreme Materials Research Center at the Korea Institute of Science and Technology ...

If you are a woman who spends most days paralyzed about what to wear, you may need a capsule wardrobe. This kind of clothing ...

With carefully crafted blends, VitaHealth’s CHARGE-UP supplement series enhances relaxation and sleep for improved well-being ...

Protagonist and Johnson & Johnson report positive Phase 3 data on icotrokinra in adolescent plaque psoriasis, showing high ...

People who love Phish do so with a quasi-religious devotion. People who dislike Phish do so with an equal fervor.

Pfizer has ended development of danuglipron, an oral GLP-1 drug for weight management, citing clinical data and regulatory input.

Once thought improbable, in vitro human models are demonstrating technological prowess in a growing range of applications.